In this study, we have unveiled that SGLT2 inhibitors exhibit the capacity to notably reduce 18F-FDG uptake in skeletal muscle compared with that of insulin under hyperglycemic condition, and enhance the tumor-to-skeletal muscle contrast. This evidence concerns the gene SLC5A2 and neoplasm.